- 1 Title: Effect of Antibiotic and Steroid Treatment on Leptospirosis Outcomes: A Single-Center
- 2 Retrospective Cohort Study in the Transcarpathian Region of Ukraine

3 Author names and affiliations.

- 4 Pavlo Petakh^{1,2*}, Valentyn Oksenych^{3*}, Mykhailo Poliak^{4,5}, Ivan Poliak⁵, Anton Kohutych⁵,
 5 Oleksandr Kamyshnyi²
- ⁶ ¹Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine;
- 7 ²Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National
- 8 Medical University, Ternopil, Ukraine;
- ⁹ ³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen,
- 10 5020 Bergen, Norway;
- ⁴Department of Pediatrics with Pediatric Infectious Diseases, Uzhhorod National University, 88000
- 12 Uzhhorod, Ukraine;
- ⁵Transcarpathian Regional Clinical Infectious Hospital, Uzhhorod, Ukraine;
- 14 Corresponding author: Department of Biochemistry and Pharmacology, Uzhhorod National
- 15 University, Uzhhorod, Ukraine; <u>pavlo.petakh@uzhnu.edu.ua</u> (P.P.)
- 16 Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020
- 17 Bergen, Norway; <u>valentyn.oksenych@uib.no (V.O.)</u>

19 Abstract

- 20 Leptospirosis presents a significant health challenge in the Transcarpathian region of Ukraine, with
- 21 higher incidence rates and mortality compared to national averages. We conducted a retrospective
- cohort study to investigate the effects of antibiotic and steroid treatments on outcomes in leptospirosis
- 23 patients. Our analysis of clinical and laboratory data from a single center revealed that dexamethasone
- showed significant effects on various clinical variables, as did investigated antibiotics. Particularly,
- 25 direct bilirubin levels emerged as a strong predictor of death. These findings provide valuable insights
- 26 for clinicians in managing leptospirosis, aiding in outcome prediction and treatment decision-making
- 27 not only in the Transcarpathian region but globally.
- 28 Keywords: leptospirosis; corticosteroids; outcome; antibiotic; dexamethasone; predictors
- 29

31 **1. Introduction**

Leptospirosis, a disease primarily found in tropical regions, is a zoonotic illness transmitted through contact with the urine of animals, particularly rats [1]. Its clinical manifestations range from mild to severe, posing life-threatening consequences. Symptoms often mimic those of other infectious diseases, such as influenza [2]. Severe cases, affecting approximately 5% to 15% of individuals, manifest with acute renal failure, acute respiratory distress syndrome, pulmonary issues, hypotension, icterus, and altered mental status [3-7].

In the Transcarpathian region, leptospirosis persists as a prevalent zoonotic disease. Between 2005
and 2015, 420 cases were reported, with an incidence three times higher than the national average.
The case fatality rate (CFR) for leptospirosis in Transcarpathia averages 12.5%, exceeding the
national level of 9.8% [8-10].

Analysis reveals a significant increase in the notification rate of leptospirosis in Ukraine in 2023. This
surge is primarily attributed to the rising incidence of leptospirosis in Transcarpathia, accounting for
150 cases out of the total 433 in Ukraine, and the Ivano-Frankivsk region, contributing 34 cases [11]
(Figure 1).

Pathogenic Leptospira, responsible for the disease, are excreted in the urine of rats, with humans inadvertently becoming hosts and facing potentially life-threatening consequences [7]. Rats, however, remain immune to fatal infection, serving as natural reservoirs. Most human leptospiral infections are either mild or asymptomatic. Those who do develop the illness typically experience an abrupt onset of symptoms, including fever, rigors, myalgias, and headache [6, 9].

The disease unfolds in two phases [12]. The initial phase involves an acute febrile bacteraemia lasting 2 to 9 days, followed by a period of reduced or no fever and apparent improvement. The second phase, known as the "immune" phase, is characterised by renewed fever and the emergence of complications. Approximately 5%–15% of patients may progress to Weil's disease, with pulmonary involvement being a notable feature (20%–70%) [7]. Pulmonary complications range from mild cough to severe symptoms like haemoptysis and Acute respiratory distress syndrome (ARDS), the latter carrying a high mortality rate of around 50% [13-15].

The role of corticosteroids in treating severe leptospirosis, especially in addressing pulmonary complications like ARDS, has been explored in a limited number of studies. The argument posits that multi-organ failure in leptospirosis may result from an overactive immune system rather than the direct effects of the pathogen [16]. Therefore, the use of therapeutic doses of steroids is considered to counteract immune activation, potentially reducing mortality and morbidity in severe leptospirosis cases [17]. However, the efficacy of corticosteroids remains uncertain due to the scarcity of studies.

This study aims to investigate the effects of antibiotic and steroid treatment on outcomes in patients diagnosed with leptospirosis within the Transcarpathian Region of Ukraine. Through a retrospective analysis of clinical and laboratory data from a single-center cohort, we aim to assess the impact of these treatments on patient morbidity and mortality rates. Additionally, we aim to explore potential associations between treatment regimens and clinical outcomes, thereby providing significant contributions to the understanding and management of leptospirosis in this geographical area.

70 2. Material and Methods

71 2.1. Study design and diagnostic criteria

We conducted a retrospective single-center cohort study. All medical records were obtained from the Transcarpathian Regional Clinical Infectious Diseases Hospital, Ukraine. Confirmation of diagnosis was determined by the order of the Ministry of Health of Ukraine No. 905 of December 28, 2015. This includes fever or at least two of the following symptoms: chills, headache, myalgia, conjunctival hyperemia, skin and mucous membrane hemorrhages, rash, jaundice, myocarditis, meningitis, kidney failure, respiratory manifestations such as hemoptysis, and laboratory confirmation by Polymerase Chain Reaction (PCR) or MAT (Microscopic Agglutination Test).

Inclusion Criteria: Patients included in this study met the following criteria: diagnosed with leptospirosis according to the criteria outlined by the Ministry of Health of Ukraine; with medical records available at the Transcarpathian Regional Clinical Infectious Diseases Hospital; confirmed laboratory diagnosis by PCR or MAT; complete clinical and laboratory data for analysis; aged 18 years and older; and non-pregnant.

Exclusion Criteria: Patients were excluded from the study if they met any of the following criteria:
incomplete medical records or missing key diagnostic information; incomplete or inconsistent
laboratory confirmation results; history of receiving medications that could interfere with the study
variables or outcomes; younger than 18 years old; or pregnant.

88 2.2. Patient Stratification and Grouping

We have grouped these patients into different groups for comparing clinical and laboratory data. 89 Firstly, based on sex, males (n=27) and females (n=11). Secondly, based on steroid treatments, the 90 majority received dexamethasone 8 mg per day (n=29), while a few received methylprednisolone 250 91 mg per day (n=2), and others included patients prescribed prednisolone 1 mg/kg/day or combination 92 steroid types (n=4), with 3 patients not receiving steroids. Next, we grouped the patients based on 93 antibiotic treatment into large groups, i.e. those treated with cephalosporins (n=17), benzylpenicillins 94 (n=8), and others treated with carbapenems or macrolides (n=13). Finally, the patients were also 95 grouped based on outcomes, i.e. 35 survivors and 3 non-survivors. 96

97 *2.3 Statistical analysis*

Power analysis was conducted to ascertain the appropriate sample size necessary to detect statistically
significant effects or differences in our study variables, while maintaining a desired level of statistical
power.

Ouantitative variables following a non-normal distribution were described using the median (Me) and 101 102 lower and upper quartiles (Q1 - Q3). Categorical data were described using absolute and relative frequencies. Comparisons of three or more groups on a quantitative variable with a distribution 103 differing from normality were made using the Kruskal-Wallis test, with Dunn's criterion and Holm 104 correction applied as a *post hoc* method. The Wilcoxon test was employed for comparing quantitative 105 variables following a non-normal distribution between two matched samples. The Mann-Whitney U-106 test was used to compare two groups on a quantitative variable with a distribution differing from 107 normality. Frequencies in the analysis of multifield contingency tables were compared using 108 Pearson's chi-square test. 109

ROC analysis was utilized to assess the diagnostic performance of quantitative variables in predicting
a categorical outcome. The optimal cut-off value of the quantitative variable was estimated using
Youden's J statistic.

113 Statistical significance was determined at p < 0.05.

114 **3. Results**

115 *3.1. Descriptive analysis and sex-dependent changes in variables*

Overall, 38 patients were included in our study, of whom 35 survived and 3 died (7.89%). The sociodemographic and clinical presentations, and laboratory findings of all confirmed patients are shown in Table 1.

The 38 patients comprised 27 (71.1%) males and 11 (28.9%) females, with a median age of 119 50.00 years (Table 2). Additionally, we conducted a sex-dependent investigation of clinical and 120 laboratory variables on admission. We found significant changes in Mean Corpuscular Volume 121 (MCV) (p = 0.002), with males having 91.00 (88.50 – 94.30) fL and females having 87.00 (83.50 – 122 88.50) fL. Males had statistically higher Alanine Aminotransferase (ALT) levels (p = 0.0048) than 123 females, with values of 93.30 (65.20 - 134.15) U/L compared to 61.50 (38.75 - 100.55) U/L, 124 respectively. Similarly, males had higher Aspartate Aminotransferase (AST) levels (p = 0.020) at 125 81.30 (54.90 – 148.95) U/L compared to females at 47.00 (30.55 – 73.55) U/L. 126

127 3.2. Effect of steroid type on clinical and laboratory findings

- Most patients took dexamethasone, comprising 29 out of 38 patients (76.3%). Additionally, only 2 patients (5.3%) received methylprednisolone. Four patients were administered other types of steroids, while three patients did not receive any steroid treatment during their hospitalization.
- When we compared laboratory findings before admission and after discharge, we found 131 statistically significant changes only in the group that took dexamethasone. The statistically 132 significant changes were observed in Lymphocytes (LYM) levels (on admission: 0.79×10^{9} /L (0.44 133 -1.45), on discharge: 2.30 ×10⁹/L (1.59 - 2.99), p < 0.001), Mid-sized Cells (MID) (on admission: 134 0.30×10^{9} /L (0.14 – 0.47), on discharge: 0.71 × 10⁹/L (0.56 – 0.81), p = 0.002), Granulocytes (GRA) 135 levels (on admission: $8.18 \times 10^{9}/L$ (6.25 – 12.16), on discharge: $6.28 \times 10^{9}/L$ (5.00 – 7.87), p = 0.033), 136 Red Blood Cells (RBC) (on admission: $4.64 \times 10^{12}/L$ (4.17 - 4.91), on discharge: $4.30 \times 10^{12}/L$ (3.63137 -4.66), p = 0.004), MCV (on admission: 90.00 fL (87.00 - 92.00), on discharge: 93.00 fL (89.00 -138 95.00), p = 0.004), Platelets (PLT) levels (on admission: $123.00 \times 10^{9}/L$ (68.00 - 182.00), on 139 discharge: 320.00×10^{9} /L (204.00 - 350.00), p < 0.001), AST (on admission: 72.30 U/L (37.30 -140 141 122.00), on discharge: 41.50 U/L (30.50 - 58.10), p = 0.016), Direct bilirubin (on admission: 14.40) μ mol/L (5.68 – 68.70), on discharge: 10.50 μ mol/L (5.70 – 21.20), p = 0.026), and Urea levels (on 142 143 admission: 9.63 mmol/L (8.22 - 23.02), on discharge: 7.80 mmol/L (6.65 - 8.63), p = 0.005). All other laboratory parameters such as White Blood Cells (WBC) (×10⁹/L), Erythrocyte Sedimentation 144 Rate (ESR) (mm/hr), Hemoglobin (HGB) (g/L), ALT (U/L), Serum Creatinine (µmol/L), glucose 145 (mmol/L), Gamma-Glutamyl Transferase (GGT) (U/L), Total Bilirubin (µmol/L), Total Protein (g/L) 146 did not show significant differences between admission and discharge (p > 0.05) (Figure 2). 147

148 3.3. Effect of antibiotic treatment on clinical and laboratory findings

We divided patients into 3 groups, i.e. those who were prescribed cephalosporins - 17 patients, those who were prescribed benzylpenicillin - 8 patients, and a group receiving alternative antimicrobial therapy - 13 patients. We compared the differences in the same indicators as when comparing the effects of steroids.

When comparing laboratory findings before admission and after discharge, we observed 153 statistically significant changes in the LYM (p=0.002), MID (p=0.027), MCV (p=0.006), PLT 154 (p=0.003), AST (p=0.015), glucose (p=0.045), Total Bilirubin (p=0.009), Direct bilirubin (p=0.015), 155 and Urea (p=0.013) for the group treated with cephalosporins. Patients treated with benzylpenicillins 156 exhibited statistically significant changes in LYM (p=0.039), MID (p=0.028), RBC (p=0.039), HGB 157 (p=0.028), and PLT (p=0.039). Patients receiving alternative antimicrobial therapy experienced 158 significant changes in LYM (p=0.033), RBC (p=0.008), MCV (p=0.033), PLT (p=< 0.001), Serum 159 Creatinine (p = < 0.001), Direct bilirubin (p = 0.048), and Urea (p = 0.010) (Table 3). When we compared 160 the effect of antibiotics and steroids on the length of stay (LoS) and outcomes, we did not find any 161 significant differences across the groups (Figure 3). 162

163 *3.4. Effect of laboratory variables on outcome*

The non-survivor group had statistically higher serum creatinine levels on admission compared to the survivor group $(137.30 \ [111.80 - 321.90] \text{ vs. } 541.30 \ [506.10 - 570.60], p = 0.032)$ and GGT levels $(75.60 \ [49.85 - 125.55] \text{ vs. } 185.30 \ [163.75 - 442.35], p = 0.032)$. Total bilirubin levels were significantly higher in the non-survivor group compared to the survivor group (491.60 $[343.95 - 563.30] \text{ vs. } 25.90 \ [11.35 - 82.76], p = 0.010)$, as were direct bilirubin levels (257.10 [199.30 $- 398.85] \text{ vs. } 14.40 \ [5.84 - 53.80], p = 0.010)$. Additionally, urea levels were higher in the nonsurvivor group (30.80 \ [30.59 - 38.15] \text{ vs. } 9.63 \ [8.20 - 21.25], p = 0.019).

Moreover, we conducted Receiver Operating Characteristic (ROC) analysis. We found that all variables had 100% sensitivity as potential predictors of death, except for GGT, which had a sensitivity of 66.8%. The specificity was lowest for GGT (77.1%), followed by serum creatinine (85.7%), total bilirubin and urea (both 88.6%), and the highest specificity was for direct bilirubin (91.4%) (Figure 4).

176 **4. Discussion**

The Transcarpathian region experienced a significantly higher notification rate in 2023, with 178 150 out of 433 reported cases originating from this area. Situated in the western part of Ukraine, the 179 region shares borders with Romania, Hungary, Poland, and Slovakia [8]. It sustains an above-average 180 human population density, with 63% residing in rural regions, which may impact notification rates 181 [18].

We observed that males had higher levels of transaminases such as AST, ALT, and GGT, but this did not affect outcomes. Our findings align with a study conducted in Germany, which revealed that male patients were more likely than female patients to be hospitalized and exhibit symptoms of severe leptospirosis, including jaundice, renal impairment, and haemorrhage [19].

Only four studies were found that investigated the role of steroids in clinical outcomes in leptospirosis. In three of these studies, methylprednisolone was administered at the initiation of treatment, albeit at varying doses. They suggested a potential beneficial role of steroids, particularly in patients with lung involvement [20-22]. However, the study that employed dexamethasone at the initiation failed to show a treatment benefit and, notably, reported an elevated incidence of nosocomial infections [23].

In regards to the effect of antibiotics on leptospirosis, we found a newly conducted meta-analysis involving 920 patients and 8 antibiotics. The analysis revealed that six antibiotics resulted in significantly shorter defervescence times compared to the control group. These antibiotics include cefotaxime, azithromycin, doxycycline, ceftriaxone, penicillin, and penicillin or ampicillin. However, antibiotics were not found to be effective in reducing mortality or hospital stays [24].

Lastly, concerning factors influencing leptospiral outcomes, we conducted our own metaanalysis of clinical predictors involving 1714 patients with leptospirosis. We found that patients with severe outcomes were more likely to experience dyspnea, oliguria, and hemorrhagic symptoms compared to non-severe patients [9].

201 **5.** Conclusions

We observed that dexamethasone had a statistically significant effect on certain clinical variables, such as LYM, MID, GRA, Platelet levels, AST, direct bilirubin, and urea levels. Similarly, cephalosporins showed significant effects on LYM, MID, Platelet, AST, total bilirubin, direct bilirubin, and urea levels. Notably, direct bilirubin levels emerged as one of the strongest predictors of death in leptospirosis, exhibiting high sensitivity and specificity. These findings have implications for clinicians not only in the Transcarpathian region but also for practitioners worldwide.

208 6. Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

211 **7. Funding**

This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors.

214 8. Author Contributions

Conceptualization, and writing—original draft preparation, P.P.; writing—review and editing, M.P.,
A.K., V.O., I.P.; supervision, O.K.; visualization, O.K., P.P.; All authors have read and agreed to the
published version of the manuscript.

218 9. Institutional Review Board Statement

219 The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics

220 Committee of Uzhhorod National University (protocol code 5/1 on 30 May 2024).

221 10. Data Availability Statement

222 The data presented in this study are available on request from the corresponding author.

223 11. References

[1] Haake DA, Levett PN. Leptospirosis in humans. J Leptospira leptospirosis. 2015:65-97.

225 [2] Philip N, Lung Than LT, Shah AM, Yuhana MY, Sekawi Z, Neela VK. Predictors of severe

226 leptospirosis: a multicentre observational study from Central Malaysia. J BMC Infectious Diseases.

227 2021;21(1):1-6.

- 228 [3] Spichler AS, Vilaça PJ, Athanazio DA, Albuquerque JO, Buzzar M, Castro B, et al. Predictors
- of lethality in severe leptospirosis in urban Brazil. The American journal of tropical medicine and
 hygiene. 2008;79(6):911.
- [4] Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in
 leptospirosis: a prospective cohort study in Khon Kaen, Thailand. International Journal of Infectious
 Diseases. 2002;6(1):52-9.
- [5] Doudier B, Garcia S, Quennee V, Jarno P, Brouqui PJCM, Infection. Prognostic factors
 associated with severe leptospirosis. Wiley Online Library; 2006. p. 299-300.
- 236 [6] Petakh P, Isevych V, Mohammed IB, Nykyforuk A, Rostoka L. Leptospirosis: Prognostic
- Model for Patient Mortality in the Transcarpathian Region, Ukraine. Vector borne and zoonotic
 diseases (Larchmont, NY). 2022;22(12):584-8.
- 239 [7] Petakh P, Isevych V, Kamyshnyi A, Oksenych V. Weil's Disease-Immunopathogenesis,
- 240 Multiple Organ Failure, and Potential Role of Gut Microbiota. Biomolecules. 2022;12(12).
- 241 [8] Markovych O, Tymchyk V, Kolesnikova I. Leptospirosis in Zakarpattia Oblast (2005–2015).
- 242 Vector-Borne and Zoonotic Diseases. 2019;19(5):333-40.
- Petakh P, Rostoka L, Isevych V, Kamyshnyi A. Identifying risk factors and disease severity
 in leptospirosis: A meta-analysis of clinical predictors. Tropical doctor. 2023;53(4):464-9.
- 245 [10] Petakh P, Kamyshnyi A, Tymchyk V, Armitage R. Infectious diseases during the Russian-
- 246 Ukrainian war Morbidity in the Transcarpathian region as a marker of epidemic danger on the EU
- border. Public Health in Practice. 2023;6:100397.
- [11] Pavlo P, Viktoriia T, Oleksandr K. Surveillance of human leptospirosis infections in Ukraine
 between 2018 and 2023 Front Public Health. 2024;12.
- [12] Xavier V, Baby B, George JM, Ittyachen AM. Covid-19 and leptospirosis, pulmonary
 involvement and response to steroids: A comparative observational study from a rural Tertiary care
 center in Kerala. Journal of family medicine and primary care. 2022;11(1):294-8.
- [13] Gulati S, Gulati A. Pulmonary manifestations of leptospirosis. Lung India : official organ of
 Indian Chest Society. 2012;29(4):347-53.
- [14] Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CRR. Pathology and pathophysiology of
 pulmonary manifestations in leptospirosis. J Brazilian Journal of Infectious Diseases.
 2007;11(1):142-8.
- [15] Vieira SR, Brauner JS. Leptospirosis as a cause of acute respiratory failure: clinical features
 and outcome in 35 critical care patients. The Brazilian journal of infectious diseases : an official
 publication of the Brazilian Society of Infectious Diseases. 2002;6(3):135-9.
- 261 [16] Limothai U, Lumlertgul N, Sirivongrangson P, Kulvichit W, Tachaboon S, Dinhuzen J, et al.
- The role of leptospiremia and specific immune response in severe leptospirosis. J Scientific reports.
 2021;11(1):1-9.

- [17] Petakh P, Nykyforuk A. Predictors of lethality in severe leptospirosis in Transcarpathian
 region of Ukraine. Le infezioni in medicina. 2022;30(2):272-6.
- [18] Wasiński B, Dutkiewicz J. Leptospirosis-current risk factors connected with human activity
 and the environment. Annals of agricultural and environmental medicine : AAEM. 2013;20(2):23944.
- [19] Jansen A, Stark K, Schneider T, Schöneberg I. Sex differences in clinical leptospirosis in
 Germany: 1997-2005. Clinical infectious diseases : an official publication of the Infectious Diseases
- 271 Society of America. 2007;44(9):e69-72.
- 272 [20] Ittyachen M A, Vk L, Ck E, Joseph M. Methylprednisolone as adjuvant in treatment of acute
- respiratory distress syndrome owing to leptospirosis A pilot study. Indian Journal of Critical Care
 Medicine (ISSN: 0972-5229) Vol 9 Num 3. 2005;9.
- 275 [21] Kularatne SA, Budagoda BD, de Alwis VK, Wickramasinghe WM, Bandara JM, Pathirage
- 276 LP, et al. High efficacy of bolus methylprednisolone in severe leptospirosis: a descriptive study in Sri
- 277 Lanka. Postgraduate medical journal. 2011;87(1023):13-7.
- [22] Shenoy VV, Nagar VS, Chowdhury AA, Bhalgat PS, Juvale NI. Pulmonary leptospirosis: an
 excellent response to bolus methylprednisolone. Postgraduate medical journal. 2006;82(971):602-6.
- 280 [23] Niwattayakul K, Kaewtasi S, Chueasuwanchai S, Hoontrakul S, Chareonwat S, Suttinont C,
- et al. An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct
- therapy in patients with pulmonary involvement associated with severe leptospirosis. Clinical
- 283 microbiology and infection : the official publication of the European Society of Clinical Microbiology
- and Infectious Diseases. 2010;16(8):1207-12.
- 285 [24] Ji Z, Jian M, Su X, Pan Y, Duan Y, Ma W, et al. Efficacy and safety of antibiotics for treatment
- of leptospirosis: a systematic review and network meta-analysis. Systematic reviews. 2024;13(1):108.

Table 1. Demographic and Clinical Characteristics of Patients with Leptospirosis in the Transcarpathian Region of Ukraine

	Abs.	%
	Sex	I
Male	27	71.1
Female	11	28.9
	Serogroups	
Hebdomadis	10	26.3
Canicola	4	10.5
Clinical	3	7.9
Others	2	5.3
Pomona	3	7.9
Sejroe	5	13.2
Icterrohaemorrhagiae	3	7.9
Cynopteri	7	18.4
Australis	1	2.6
	Outcome	
Survive	35	92.1
Non-survive	3	7.9
	Antibiotic	
Cephalosporins	17	44.7
Benzylpenicillins	8	21.1
Others	13	34.2
	Steroids	
None	3	7.9
Dexamethasone	29	76.3
Methylprednisolone	2	5.3
Others	4	10.5

290

291

	-	
Variables	Median (Me)	Q1 – Q3 (Interquartile Range)
Age (years)	50.00	44.25 - 63.75
Length of Stay (LoS) (days)	10.00	7.00 - 11.75
WBC (×10 ⁹ /L)	10.73	6.87 - 14.81
LYM (×10 ⁹ /L)	0.71	0.43 - 1.45
MID (×10 ⁹ /L)	0.31	0.14 - 0.63
GRA (×10 ⁹ /L)	8.18	6.25 - 13.38
ESR (mm/hr)	46.50	30.00 - 75.25
RBC (×10 ¹² /L)	4.38	4.08 - 4.91
HGB (g/L)	128.00	113.50 - 140.75
MCV (fL)	89.50	87.00 - 92.00
PLT (×10 ⁹ /L)	116.50	68.00 - 181.25
ALT (U/L)	92.15	55.00 - 128.85
AST (U/L)	76.15	44.52 - 123.35
Serum Creatinine (µmol/L)	138.90	112.67 - 421.27
Glucose (mmol/L)	7.28	6.55 - 9.04
GGT (U/L)	85.75	52.62 - 157.88
Total Bilirubin (µmol/L)	34.00	12.47 – 121.80
Direct Bilirubin (µmol/L)	19.35	6.22 - 91.58
Total Protein (g/L)	61.20	55.25 - 63.27
Urea (mmol/L)	10.82	8.26 - 23.08

293	Table 2. Clinical and Laborator	y Findings at Admission for Patients with Leptospirosis	

294

Table 3. Effect of Antibiotics on Laboratory Findings

Variables	Group	On Admission (Median [Q1 – Q3])	On Discharge (Median [Q1 – Q3])	P value
WBC (×10 ⁹ /L)	Cephalosporins	8.39 (6.59 – 14.01)	9.25 (7.86 – 12.86)	0.747
	Benzylpenicillins	9.87 (7.49 – 12.73)	8.96 (6.77 – 11.04)	0.844
	Others	11.68 (7.12 – 18.00)	9.62 (7.31 – 12.08)	0.414
LYM (×10 ⁹ /L)	Cephalosporins	0.62 (0.39 - 1.20)	2.50 (1.68 - 3.02)	0.002*
	Benzylpenicillins	0.60 (0.43 – 0.86)	1.73 (1.25 – 1.91)	0.039*
	Others	1.18 (0.53 – 2.14)	2.05 (1.58 - 2.81)	0.033*
MID (×10 ⁹ /L)	Cephalosporins	0.24 (0.14 - 0.39)	0.68 (0.43 – 0.81)	0.027*
	Benzylpenicillins	0.34 (0.29 – 0.51)	0.84 (0.54 - 1.09)	0.028*
	Others	0.36 (0.13 – 0.99)	0.71(0.62 - 0.75)	0.497
GRA (×10 ⁹ /L)	Cephalosporins	7.39 (6.15 – 12.16)	6.73 (5.08 - 8.71)	0.109
	Benzylpenicillins	8.46 (6.70 – 11.77)	6.03 (5.00 - 7.95)	0.250
	Others	8.54 (6.25 – 15.20)	6.94 (4.70 - 7.87)	0.094
ESR (mm/hr)	Cephalosporins	40.00 (27.00 - 63.00)	33.00 (20.00 - 60.00)	0.378
	Benzylpenicillins	63.50 (31.50 – 79.25)	51.50 (34.50 - 75.25)	0.641
	Others	59.00 (41.00 - 82.00)	49.00 (41.00 - 70.00)	0.127
RBC (×10 ¹² /L)	Cephalosporins	4.48 (4.24 - 5.01)	4.33 (3.89 - 4.93)	0.207
	Benzylpenicillins	4.01 (3.80 - 4.80)	3.67 (3.56 - 4.07)	0.039*
	Others	4.38 (4.16 - 4.80)	4.37 (3.46 - 4.50)	0.008*
HGB (g/L)	Cephalosporins	130.00 (123.00 - 140.00)	125.00 (116.00 - 144.00)	0.782
	Benzylpenicillins	121.50 (112.75 – 127.25)	115.50 (112.00 – 117.75)	0.028*
	Others	127.00 (110.00 - 142.00)	127.00 (102.00 – 138.00)	0.340
MCV (fL)	Cephalosporins	90.00 (87.00 – 92.00)	92.00 (89.00 – 94.00)	0.006*
	Benzylpenicillins	90.00 (86.75 – 93.00)	91.50 (88.50 – 95.25)	0.250
	Others	89.00 (87.00 – 95.00)	90.00 (88.00 – 97.00)	0.033*
PLT (×10 ⁹ /L)	Cephalosporins	136.00 (73.00 – 229.00)	346.00 (293.00 – 398.00)	0.003*
	Benzylpenicillins	85.00 (49.75 – 150.50)	(132.25 - 338.50)	0.039*
	Others	107.00 (68.00 - 139.00)	278.00 (228.00 – 339.00)	< 0.001*
ALT (U/L)	Cephalosporins	93.00 (41.60 - 169.30)	85.40 (64.40 – 106.80)	0.159
	Benzylpenicillins	85.65 (68.72 – 247.22)	68.50 (62.27 – 132.75)	0.250

	1	1	1	1
	Others	85.30	55.90	0.839
		(53.80 - 120.60)	(41.10 - 98.50)	
AST (U/L)	Cephalosporins	81.30	49.30	0.015*
		(39.10 - 135.80)	(34.50 - 58.10)	
	Benzylpenicillins	69.80	49.15	0.109
		(48.12 – 156.90)	(27.60 - 93.25)	
	Others	76.20	37.50	0.168
		(44.10 - 103.00)	(27.60 - 53.90)	
Serum	Cephalosporins	119.70	105.90	0.109
Creatinine		(107.10 - 243.80)	(102.90 - 126.40)	
(µmol/L)	Benzylpenicillins	264.80	117.75	0.461
		(124.55 - 524.65)	(103.17 - 262.07)	
	Others	144.10	109.90	< 0.001*
<u>C1</u>	0 1 1	(115.30 - 437.20)	(101.20 - 132.50)	0.045*
Glucose	Cephalosporins	6.59(6.45 - 7.77)	6.40(6.00-6.76)	0.045*
(mmol/L)	Benzylpenicillins	8.47 (6.75 - 9.48)	6.37(5.88-7.86)	0.109
	Others	7.80 (6.77 – 9.10)	6.78 (6.53 - 8.91)	0.376
GGT (U/L)	Cephalosporins	120.00	79.90	0.064
		(57.80 - 172.70)	(49.10 - 157.60)	
	Benzylpenicillins	77.25	76.70	0.148
		(50.67 - 123.05)	(45.30 - 110.97)	
	Others	74.80	74.80	0.735
T-4-1 D:1:1:		(47.60 - 125.60)	(61.70 - 110.00)	
Total Bilirubin	Cephalosporins	25.90	12.40	0.009*
$(\mu mol/L)$		(10.80 – 56.60) 108.66	(11.10 – 29.20) 43.35	
	Benzylpenicillins	(44.82 - 261.20)	(31.35 – 176.55)	
		20.50	(31.33 - 170.33) 20.10	0.080
	Others	(14.70 - 159.30)	(12.70 - 38.80)	
Direct bilirubin		14.40 (5.68 –	7.80	0.015*
(µmol/L)	Cephalosporins	37.10)	(5.40 - 19.40)	
(µ1101/L)		72.81	24.30	
	Benzylpenicillins Others	(31.20 - 170.40)	(17.12 - 99.60)	0.461
		11.10	9.80	
		(6.90 - 99.20)	(6.90 - 20.50)	0.048*
Total protein	Cephalosporins Benzylpenicillins	58.53	60.50	0.469 0.641
(g/L)		(54.70 - 63.30)	(58.60 - 62.30)	
(5/12)		59.75	59.53	
		(56.23 - 63.06)	(54.25 - 61.73)	
	Others	62.30	61.80	0.244
		(59.60 - 63.20)	(58.80 - 63.00)	
Urea (mmol/L)	Cephalosporins	9.63 (8.22 –		0.013*
		20.39)	7.35 (6.52 - 8.18)	
	Benzylpenicillins	20.52 (8.12 -	9.45 (7.56 –	0.945
		30.87)	18.40)	
		17.45 (8.72 –		
	Others	23.02)	7.92 (6.65 - 8.63)	0.010*
			1	1

297

- **Figure 1.** Average annual rate of confirmed leptospirosis cases per 100,000 population, European
- 300 Union/European Economic Area, 2010–2021. Adapted from ECDC [25]. The average number of
- 301 leptospirosis cases in Ukraine is one of the highest in Europe, amounting to 0.73 per 100,000 people
- for the period 2010-2021. For comparison, in neighboring countries, the rate is 0.1 in Poland, 0.15 in
- 303 Slovakia, and 0.34 in Romania.
- Figure 2. Facet box plots of laboratory findings on admission and discharge in patients who tookdexamethasone
- 306 Statistically significant changes were observed in multiple parameters including LYM, MID, GRA,
- 307 RBC, MCV, PLT, AST, Direct bilirubin, and Urea levels.
- **Figure 3.** Box plots illustrating the Effect of steroids and antibiotics on Length of Stay (LoS).
- 309 No significant changes were observed in patients receiving either steroids or antibiotics
- **Figure 4.** Direct bilirubin levels on admission as a potential predictor of lethality in leptospirosis.
- A. Box plot illustrating direct bilirubin levels on admission in surviving and non-surviving patients.
- B. ROC curve depicting the relationship between the probability of outcome and direct bilirubin.
- 313 C. Analysis of sensitivity and specificity of outcome based on direct bilirubin levels.









